Drug Trial Radar · NCT05256290
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
220
Planned (sponsor's estimate)
Start
Mar 31, 2022
Primary completion
Mar 2028
Study completion Jun 2028
Sponsor
- Lead sponsor
- Black Diamond Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of silevertinib (BDTX-1535). The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only). All patients will self-administer silevertinib (BDTX-1535) monotherapy by mouth in 21-day cycles. Phase 1 enrollment is now complete. Phase 2 is currently ongoing.
Conditions
- Non-Small Cell Lung Cancer
- Advanced Non-Small Cell Squamous Lung Cancer
- Metastatic Lung Non-Small Cell Carcinoma
- Metastatic Lung Cancer
- NSCLC
- Advanced Lung Carcinoma
- Epidermal Growth Factor Receptor C797S
- Epidermal Growth Factor Receptor G719X
- EGF-R Positive Non-Small Cell Lung Cancer
- EGFR-TKI Resistant Mutation
Interventions
silevertinib monotherapyDrug
Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 Dose Escalation: To determine the maximum tolerated dose (MTD), if one exists, and the preliminary recommended Phase 2 dose(s) (RP2D[s]) of silevertinib (BDTX-1535)Time frame: The first treatment 21-day cycle (Cycle 1)
- Phase 2 (Cohorts 1, 2, and 3): To assess antitumor efficacy of silevertinib (BDTX-1535)Time frame: Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)
- Phase 2 Cohort 4 Only: To assess the safety and tolerability of silevertinib at the 150 mg QD doseTime frame: Through study completion, approximately 1 year
Locations
19 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama
Birmingham, Alabama · Recruiting
Banner MD Anderson Cancer Center
Gilbert, Arizona · Recruiting
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, California · Recruiting
Cedars Sinai Medical Center
Los Angeles, California · Recruiting
Sibley Memorial Hospital Johns Hopkins Medicine
Washington D.C., District of Columbia · Recruiting
Mayo Clinic- Jacksonville
Jacksonville, Florida · Recruiting
Miami Cancer Institute - Baptist Health South Florida
Miami, Florida · Recruiting
UHP- University of Hawaii Cancer Center
Honolulu, Hawaii · Recruiting
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Chicago, Illinois · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Mayo Clinic- Rochester
Rochester, Minnesota · Recruiting
Montefiore Medical Center
The Bronx, New York · Recruiting
University of Pittsburgh Medical Center - Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
Tennessee Oncology
Nashville, Tennessee · Recruiting
Inova Schar Cancer Institute
Fairfax, Virginia · Recruiting
Next Oncology
Fairfax, Virginia · Recruiting
Fred Hutchinson Cancer Center/University of Washington
Seattle, Washington · Recruiting
BC Cancer Vancouver
Vancouver, British Columbia, Canada · Recruiting
The Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.